CVS-3983

a selective matriptase inhibitor; structure in first source

Networked: 1 relevant articles (0 outcomes, 0 trials/studies)

1.	Prostatic Neoplasms (Prostate Cancer) 11/01/2004 - "These results identify CVS-3983 as a potent inhibitor of AI prostate cancer cell invasion in vitro and established xenograft tumor growth in vivo." 11/01/2004 - "We studied the effects of CVS-3983, a selective small molecule matriptase inhibitor, on the growth of the androgen independent (AI) CWR22R and CWRSA6 human prostate cancer xenograft models. "
2.	Neoplasms (Cancer) 11/01/2004 - "CVS-3983 inhibited final mean tumor volume by 65.5% (n = 10, P = 0.0002) in the CWR22R model and by 56.2% (n = 8, P = 0.0017) in the CWRSA6 tumor model compared with vehicle-treated tumors. " 11/01/2004 - "These results identify CVS-3983 as a potent inhibitor of AI prostate cancer cell invasion in vitro and established xenograft tumor growth in vivo." 11/01/2004 - "CVS-3983, a selective matriptase inhibitor, suppresses the growth of androgen independent prostate tumor xenografts." 11/01/2004 - "Molecular analysis of the xenograft tumors demonstrated high expression levels of matriptase at the RNA and protein levels, which were not affected by CVS-3983 treatment. "